Key Points
Dec 1 (Reuters) - The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Novo Nordisk's (NOVOb.CO) popular therapies Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them...
Though also targeting the GLP-1 receptor, Eli Lilly's diabetes and weight-loss drug Mounjaro, also known as Zepbound, is not part of EMA's review because it belongs to a different molecule class that binds to two different gut hormone receptors...
[1/2]Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023..
Reuters reported in September that the U.S. Food and Drug Administration (FDA) had received 265 reports of suicidal thoughts or behaviour in patients taking GLP-1 medication between 2010 and June 2023...
The FDA-approved label of weight-loss drug Wegovy in the United States, says suicidal thoughts or attempts have been reported in clinical trials for other weight-loss medicines...
You might be interested in
The Obesity Drug Revolution Just Got Real
08, Aug, 23Wegovy reduces risk of heart attack, stroke in study, paving way for greater insurance coverage
Belgium seizes fake weight-loss drugs containing insulin
30, Oct, 23Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's (NOVOb.CO) popular obesity drug Wegovy, in which the injector pens contained insulin.
Regulators are investigating claims of suicidal thoughts and self-harm in Ozempic and Wegovy patients
12, Jul, 23European regulators are looking into about 150 reports of self-harm and suicidal thoughts in patients taking GLP-1 drugs including Ozempic and Wegovy.
Novo Nordisk says Wegovy heart benefits due to more than weight loss
11, Nov, 23Novo Nordisk (NOVOb.CO) on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday.
US diabetes patients face delays as insurers tighten Ozempic coverage
12, Dec, 23Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter doctors from prescribing the medication for weight loss.
Swedish regulator asks doctors not to prescribe diabetes drugs for weight loss
11, Dec, 23Sweden's drugs agency on Monday asked doctors to hold off on prescribing diabetes drugs for the treatment of obesity, pointing to signs that a spike in such usage has left diabetics short of medication.
Belgium bans use of Ozempic for weight loss until summer
14, Nov, 23Belgium has decided to temporarily ban the use of Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic as a weight loss treatment amid a shortage of the medicine, according to a royal decree published in the country's Official Gazette on Tuesday.
UK warns of fake Ozempic pens after hospitalisations
27, Oct, 23Britain on Thursday cautioned the public about buying fake weight-loss pens claiming to contain Novo Nordisk's diabetes drug Ozempic or weight-loss drug Saxenda after reports of a "very small number" of hospitalisations.
Analysis: Healthcare companies counter investor worries over Wegovy effect
27, Oct, 23Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't shrink their businesses.
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
05, Dec, 23Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found. It concentrated that money on an elite group of obesity specialists who advocate giving its powerful and expensive drugs to tens of millions of Americans.